Helicobacter Pylori: Patofizyoloji, Sıklık, Risk Faktörleri, Tanı ve Tedavi

Öz

Helicobacter pylori (H pylori) populasyonun %50'sinden fazla görülen ve gastrik mukozaya yerleşen spiral şekilli, flajelli, mikroaerofilik, gram (-) bir basildir. Dünya genelinde en yükseği gelişmekte olan ülkelerde bildirilen değişken bir görülme sıklığına sahiptir. Risk faktörleri ile ilgili çalışmalar özellikle sosyoekonomik faktörler üzerinde durmaktadır. İnsanlarda gastrit ve ülser ile ilişkisi net olarak kanıtlanmıştır. Enfeksiyon çocukluk çağında sıklıkla oral yolla bulaşmaktadır. Üre nefes testi, dışkı antijen testi, antikor tayini, endoskopi, histolojik inceleme, üreaz testi ve kültür tanıda kullanılan yöntemlerdendir. Antibiyoterapi ve antiasitler tek başına yeterli olmadığından birlikte kullanımları tercih edilmektedir. N-asetilsistein gibi mukolitik bir ajan ile H pylori tabakasının ortadan kaldırılması da tedavi öncesinde etkili olabilmektedir. Lactobacillus, Saccharomyces, Bifidobacterium ve Bifidobacterium clausii gibi probiyotik suşların eklenmesi de diğer bir tedavi yaklaşımıdır. İlk tercih tedaviler yetersiz kaldığında farklı antibiyotikleri içeren ikinci adım tedavilere gerek duyulabilmektedir

Anahtar Kelimeler

• Helicobacter pylori,gastrit,antibiyotik,tanı,tedavi

Helicobacter Pylori: Pathophysiology, Prevalence, Risk Factors, Diagnosis and Treatment

Öz

Helicobacter pylori (H pylori) is a spiralshaped, flagellated, micro- aerophilic gram-negative bacillus that colonizes the gastric mucosa of more than 50% of the human population. There are different findings for the prevalence of H pylori across the world with the highest prevalence in developing countries. Most of the reports on risk factors focused on socioeconomic indicators. Its relationship with gastritis and peptic ulcer in humans was proven. The infection is transmitted within the family in childhood, likely by oral transmission. Urea breath test, stool antigen test, antibody detection, endoscopy, histology, urease test, and culture are used for the diagnosis. Antibiotics and antiacidics are not sufficient alone, therefore combination treatment is preferred. Pretreatment with N-acetylcysteine as a mucolytic agent to destroy the biofilm of H pylori is effective. The addition of probiotics such as Lactobacillus spp., Saccharomyces spp., Bifidobacterium spp., and Bifidobacterium clausii as an adjunctive agent is another approach. If the first-line therapy fails, the second-line options should include different antibiotics.

Anahtar Kelimeler

• Helicobacter pylori,gastritis,antibiotics,diagnosis,treatment

Kaynakça

1. 1-Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1:1311– 1315.
2. 2-Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986; 39:353–365.
3. 3- Ruggiero P. Helicobacter pylori infection: what’s new. Curr Opin Infect Dis 2012; 25:337–344.
4. 4- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans . Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7- 14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61:1.
5. 5- Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030.
6. 6- IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7- 14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61:177.
7. 7-Solcia E, Fiocca R, Luinetti O, et al. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol 1996; 20 (Suppl 1);8-22.
8. 8- Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203:681-687.

9. 9- Cherian S, Forbes D, Sanfilippo F, et al. The epidemiology of Helicobacter pylori infection in African refugee children resettled in Australia. Med J Aust 2008; 189:438–441.
10. 10- Naito Y, Shimizu T, Haruna H, et al. Changes in the presence of urine Helicobacter pylori antibody in Japanese children in three different age groups. Pediatr Int 2008; 50:291– 294.
11. 11- Moujaber T, MacIntyre CR, Backhouse J, et al. The seroepidemiology of Helicobacter pylori infection in Australia. Int J Infect Dis 2008; 12:500–504.
12. 12- Yucel T, Aygin D, Sen S, et al. The prevalence of Helicobacter pylori and related factors among university students in Turkey. Jpn J Infect Dis 2008; 61:179–83
13. 13- Azevedo NF, Huntington J and Goodman KJ. The Epidemiology of Helicobacter pylori and Public Health Implications. Helicobacter 2009; 14 (Suppl. 1): 1–7.
14. 14- De Schryver A, Cornelis K, Van Winckel M, et al. The occupational risk of Helicobacter pylori infection among workers in institutions for people with intellectual disability. Occup Environ Med 2008; 65:587–91.
15. 15- Tschopp A, Joller H, Jeggli S, et al. Hepatitis E, Helicobacter pylori and peptic ulcers in workers exposed to sewage: a prospective cohort study. Occup Environ Med 2009; 66:45–50.
16. 16- Mitchell H and Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2002; 7(supp 1): 8-16.
17. 17- Osaki T, Mabe K, Hanawa T, et al. Ureasepositive bacteria in the stomach induce a falsepositive reaction in a urea breath test for diagnosis of Helicobacter pylori infection. J Med Microbiol 2008; 57(Pt 7):814–819.
18. 18- Peng NJ, Lai KH, Lo GH, et al. Comparison of noninvasive diagnostic tests for Helicobacter pylori infection. Med Princ Pract 2009; 18:57–61.
19. 19- Blanco S, Forne M, Lacoma A, et al. Comparison of stool antigen immunoassay methods for detecting Helicobacter pylori infection before and after eradication treatment. Diagn Microbiol Infect Dis 2008;61: 150–155.
20. 20- Peterson WL, Graham DY. Helicobacter pylori. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Ed by: Feldman M, Friedman LS, Sleisenger MH. 7th ed. Saunders company, Philadelphia. 2002; Vol 1 (Ch 39): 732-746.
21. 21- Cho YS, Chae HS, Jang SN, et al. Comparison of the 13C-urea breath test and the endoscopic phenol red mucosal pH test in the quantification of Helicobacter pylori infection loading. Korean J Intern Med 2008; 23:134– 139.
22. 22- Şimşek H, Özarslan E Helicobacter Pylori. Tözün N, Şimşek H, Özkan H at al. Clinic Gastroenterology and Hepatology. 1. Ed. 2007 Nobel, Ankara p:91-108.
23. 23- Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40:650–658.
24. 24- Satoh K, Osawa H, Yoshizawa M, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008;13:225–229.
25. 25- Rugge M, Kim JG, Mahachai V, et al. OLGA gastritis staging in young adults and country-specific gastric cancer risk. Int J Surg Pathol 2008; 16: 150–154.
26. 26- Siddique I, Al-Mekhaizeem K, Alateeqi N, et al. Diagnosis of Helicobacter pylori: improving the sensitivity of CLOtest by increasing the number of gastric antral biopsies. J Clin Gastroenterol 2008; 42:356– 360
27. 27- Sainsus N, Cattori V, Lepadatu C, et al. Liquid culture medium for the rapid cultivation of Helicobacter pylori from biopsy specimens. Eur J Clin Microbiol Infect Dis 2008;27:1209–1217.
28. 28- Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011;27:565–570.
29. 29- Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010;8:817–820.
30. 30- Vitor JM, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol 2011; 63:153 – 164.
31. 31- Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069–1079.
32. 32- Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day con- & comitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507–514.
33. 33- Schmilovitz-Weiss H, Shalev T, Chechoulin Y, et al. High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating native patients. Helicobacter 2011; 16: 229– 233.
34. 34- Albrecht P, Kotowska M, Szajewska H. Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial. J Pediatr 2011; 159:45 – 49.
35. 35- Nadir I, Yonem O, Ozin Y, et al. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J 2011;104:102–105.
36. 36- Liou JM, Chen CC, Chen MJ, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011;66:1847–1852.
37. 37- Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011; 16:234 – 240.
38. 38- Furuta T, Kato M, Sugimoto M, et al. Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. Intern Med 2011; 50:369–374.
39. 39- Malfertheiner P, Bazzoli F. Delchier et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetra- cycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377:905–913.
40. 40- Toros AB, Ince AT, Kesici B, et al. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobacter 2011; 16:225–228.
41. 41- Ghadir MR, Shafaghi A, Iranikhah A, et al. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. Turk J Gastroenterol 2011; 22:1–5.
42. 42- Tahara T, Arisawa T, Shibata T, et al. ffect of RANTES promoter genotype on the severity of intestinal metaplasia in Helicobacter pylori-infected Japanese subjects. Dig Dis Sci 2009;54:1247–52.
43. 43- Jafari F, Shokrzadeh L, Dabiri H, et al. vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. Jpn J Infect Dis 2008;61:290–3.
44. 44- Chomvarin C, Namwat W, Chaicumpar K, et al. Prevalence of Helicobacter pylori vacA, cagA, cagE, iceA and babA2 genotypes in Thai dyspeptic patients. Int J Infect Dis 2008;12:30–6.
45. 45- Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008;135:91–9.
46. 46- Kim N, Park YS, Cho SI, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245–55.
47. 47- Wu CY, Wu CH, Wu MS, et al. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009;7:427–31. 48- Van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008;22:209–24.
48. 49-Kim YS, Park SW, Kim MH, et al. Novel single nucleotide polymorphism of the VEGF gene as a risk predictor for gastroduodenal ulcers. J Gastroenterol Hepatol 2008;23:S131–9.
49. 50- Cheon JH, Kim JH, Lee SK, et al. Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study. Helicobacter 2008;13:564–71.
50. 51- Anderson LA, Murphy SJ, Johnston BT, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut 2008;57:734–9.
51. 52- Kwon JH, Chung IS, Son HS, et al. The relationship of gastrin, pepsinogen, and Helicobacter pylori in erosive reflux esophagitis. Korean J Gastroenterol 2008;51:159–66.
52. 53- Monkemuller K, Neumann H, Nocon M, et al. Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastrooesophageal reflux disease: a matched case- control study. Aliment Pharmacol Ther 2008;28:491–6.
53. 54- Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008;105: 1003–8.
54. 55- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF ⁄ ACG ⁄ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502–17.
55. 56- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF ⁄ ACG ⁄ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008;103:2890–907.
56. 57- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF ⁄ ACG ⁄ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894–909.
57. 58- Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728–38.
58. 59 Kiltz U, Zochling J, Schmidt WE, et al. Use of NSAIDs and infection with Helicobacter pylori–what does the rheumatologist need to know? Rheumatology (Oxford) 2008;47:1342–7.
59. 60- Wroblewski LE, Peek RM. Helicobacter pylori in Gastric Carcinogenesis: Mechanisms. Gastroenterol Clin N Am 2013;42: 285–298.
60. 61- Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009;15(11):971–6.
61. 62- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74–108.
62. 63- Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001;107(7):767–73.
63. 64- Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23(4): 713–39.
64. 65- Covacci A, Rappuoli R. Tyrosinephosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 2000;191(4):587–92.
65. 66- Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996;93(25):14648–53.
66. 67- Akopyants NS, Clifton SW, Kersulyte D, et al. Analyses of the cag pathogenicity island of Helicobacter pylori. Mol Microbiol 1998;28(1):37–53.
67. 68- Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000; 287(5457):1497–500.
68. 69- Kwok T, Zabler D, Urman S, et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 2007;449(7164):862–6.
69. 70- Jimenez-Soto LF, Kutter S, Sewald X, et al. Helicobacter pylori type IV secretion apparatus exploits beta1 integrin in a novel RGD-independent manner. PLoS Pathog 2009;5(12):e1000684.
70. 71- Shaffer CL, Gaddy JA, Loh JT, et al. Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteriahost cell interface. PLoS Pathog 2011;7(9):e1002237. 72- Boughan PK, Argent RH, Body-Malapel M, et al. Nucleotide-binding oligomerization domain-1 and epidermal growth factor receptor: critical regulators of beta-defensins during Helicobacter pylori infection. J Biol Chem 2006; 281(17):11637–48.
71. 73- Watanabe T, Asano N, Fichtner-Feigl S, et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest 2010;120(5):1645–62.
72. 74- Nagy TA, Wroblewski LE, Wang D, et al. b-Catenin and p120 mediate PPARdeltadependent proliferation induced by Helicobacter pylori in human and rodent epithelia. Gastroenterology 2011;141(2):553–64.
73. 75- Nagy TA, Frey MR, Yan F, et al. Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling. J Infect Dis 2009;199(5):641–51.
74. 76- Cooke CL, Torres J and Solnick JV. Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes 2013;4:6,1–9.
75. 77- Aiello AE, Diez-Roux A, Noone A-M, et al. Socioeconomic and psychosocial gradients in cardiovascular pathogen burden and immune response: the multi-ethnic study of atherosclerosis. Brain Behav Immun 2009;23:663–71.
76. 78- Tamer GS, Tengiz I, Ercan E, et al. Helicobacter pylori seropositivity in patients with acute coronary syndromes. Dig Dis Sci 2009;54:1253–6.
77. 79- Jha HC, Prasad J, Mittal A. High immunoglobulin A seropositivity for combinedChlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker. Heart Vessels 2008;23:390–6.
78. 80- Nikolopoulou A, Tousoulis D, Antoniades C, et al. Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1. Int J Cardiol 2008;130:246–50.
79. 81- Franceschi F, Niccoli G, Ferrante G, et al. CagA antigen of Helicobacter pylori and coronary instability:insight from a clinicopathological study and a meta-analysis of 4241 cases. Atherosclerosis 2009;202:535–42.
80. 82- Berrutti M, Pellicano R, Fagoonee S, et al. Potential relationship between Helicobacter pylori and ischemic heart disease: any pathogenic model? Panminerva Med 2008;50:161–3. Kucukazman M, Yacuz B, Sacikara M, et al. The relationship between updated Sydney system score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci 2009;54:604–7.
81. 83- Platonov P, Ekesbo R, Hansson A, et al. Permanent atrial fibrillation in patients without structural heart disease is not associated with signs of infection by Chlamydia pneumoniae and Helicobacter pylori. Acta Cardiol 2008;63:479–84.
82. 84- Lunetta M, Fazio G, Avena V, et al. Helicobacter pylori and atrial fibrillation. J Cardiovasc Med 2009;10:4–5.
83. 84- Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998;352:878.
84. 86- Malfertheiner P, Me ́graud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–81.
85. 87- Kurtoglu E, Kayacetin E, Ugur A. Helicobacter pylori infection in patients with autoimmune thrombocytopenic purpura. World J Gastroenterol 2004;10(14):2113-15.
86. 88- Jackson SC, Beck P, Buret AG, et al. Long-term platelet responses to Helico- bacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. Int J Hematol 2008;88:212–8.
87. 89- Tsumoto C, Tominaga K, Okazaki H, et al. Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study. Ann Hematol 2009;88:789–93.
88. 90- Song MK, Chung JS, Shin JS, et al. Outcome of immunosuppressive therapy with Helicobacter pylori eradication therapy in patients with chronic idiopathic thrombocytopenic purpura. J Korean Med Sci 2008;23:445–51.
89. 91- Sivapathasingam V, harvey MP, wilson RB. Helicobacter pylori eradication: a novel therapeutic option in chronic immune thrombocytopenic purpura. Med J Aust 2008;189:367–70.
90. 92- Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113:1231–4093- Carter D, Maor Y, Bar-Meir S, et al. Prevalence and predic- tive signs for gastrointestinal lesions in premenopausal women with iron deficiency anemia. Dig Dis Sci 2008;53:3138–44.
91. 94- Mulayim B, Celik NY, Yanik FF. Helicobacter pylori infection detected by 14Curea breath test is associated with iron deficiency anemia in pregnant women. J Obstet Gynaecol Res 2008;34:980–5.
92. 95- Cardamone M, Laex G, Harari MD, et al. Severe iron-deficiency anemia in adolescents: consider Helicobacter pylori infection. J Paediatr Child Health 2008;44:647–50.
93. 96- Fagan RP, Dunaway CE, Bruden DL, et al. Controlled, household-randomized, open-label trial of the effect of treatment of Helicobacter pylori infection on iron deficiency among children in rural Alaska: results at 40 months. J Infect Dis 2009;199:652–60.
94. 97- Haghi-Ashtiani MT, Monajemzadeh M, Motamed F, et al. Anemia in children with and without Helicobacter pylori infection. Arch Med Res 2008;39:536–40.
95. 98- Kaya AD, Gencay E, Ozrurk CE, et al. Seroprevalence of Helicobacter pylori infection in children in Northwest of Turkey: relationship with iron deficiency anemia. J Trop Pediatr 2008;54:353–4.
96. 99- Sarker SA, Mahmud H, Davidsson L, et al. Causal relationship of Helicobacter pylori with iron- deficiency anemia or failure of iron supplementation in children. Gastroenterol 2008;135:1534–42.
97. 100- Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematiceview and meta-analysis. Helicobacter 2008;13:323–40.